Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2006

View Archived Issues

Deleterious effects of metformin in stroke

Intranasal bFGF stimulates SVZ stem cells following MCAO

First picomolar D5-selective receptor antagonist presented

New studies in advanced colorectal cancers presented

Recent clinical results in gastrointestinal cancers made available

Savient explores strategic options for Rosemont Pharmaceuticals

Scavidin stops tumor development in cancer treatment models

Zenyth and MuriGen to collaborate on antiinflammatory drugs

A role for SNO in ALS and the therapeutic benefits of SNO donors

Novartis and Alnylam collaborate on RNAi therapeutics for pandemic flu

Studies support Innogenetics Alzheimer's disease tests

Cryptome completes acquisition of HealthLinx

VQD-002 to be studied for malignant tumors

BZL-101 has potential to treat aggressive late-stage breast cancer

ALGRX-3268 demonstrates significant pain relief in children in phase III trial

Positive preliminary phase IIb results for ecabet sodium in dry eye syndrome

deCODE successfully completes phase I testing for DG-041

Glycogen phosphorylase inhibitor PSN-357 begins phase IIa trial

IDM and Genesis Pharma sign agreement for Junovan in South East Europe

Acadia advances two preclinical programs

Cerimon licenses Simulect for IBD from Novartis

Ebola DNA vaccine produces immune responses in phase I study

Geron's small-molecule telomerase activators show utility for HIV/AIDS

Three-year follow-up shows Retisert improves visual acuity

Fast track designation for viral entry inhibitor PRO-140

Novel agents for gastrointestinal disorders disclosed in recent patent literature

New agents for treating thrombosis and related disorders reported in recent patents

New NMDA receptor antagonist shows neuroprotective potential in vitro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...